B7-H4‒directed antibody-drug conjugate AZD8205 (puxitatug samrotecan) in patients with advanced/metastatic solid tumors: the Phase 1/2a (BLUESTAR), first-in-human study
B7-H4 is a promising therapeutic target in solid tumors because of its frequent expression in cancer cells, limited normal tissue distribution, and immunosuppressive functions.